drugset / Trial / NCT06850285
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The is a prospective, open-label, dose-climbing clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
Timeline
- Start
- 2025-09-05
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | chimeric antigen receptor gene modified T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | chimeric antigen receptor gene modified T cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | chimeric antigen receptor gene modified T cells | Cell therapy | 5e+06 cells/kg | Intravenous |